AiCuris Anti-infective Cures GmbH, a leading company in the discovery and development of drugs against infectious diseases, today announced the start of a new clinical program with AIC499, an innovative beta-lactam antibiotic against a broad range of multidrug-resistant (MDR) Gram-negative bacteria in complicated urinary tract infections (cUTI) and complicated intra-abdominal infections (cIAI).

As a first step in the clinical development, the first-in-human phase 1 trial is currently ongoing to primarily evaluate the safety, tolerability and pharmacokinetics of single ascending doses of intravenous AIC499. The study is randomized, single-blind, placebo-controlled and conducted in 48 healthy volunteers in a single center at the Medical University of Vienna, Austria. This single dose part will be followed by a multiple ascending dose part in 36 volunteers.

Read the full press release below.